IL6 and chronic kidney disease: Similarly, a double-blind, randomized, placebo-controlled phase 2 trial of the IL-6 antibody ziltivekimab demonstrated reduced inflammatory and thrombotic markers in patients with stage 3/4 CKD at high risk of atherosclerotic events [69], reduced erythropoietic requirements in those with end-stage kidney disease (a recognised risk factor for CV disease), and promoted inflammatory hyporesponsiveness [70].